stock
Allogene Therapeutics Inc
NASDAQ | ALLO
1.10
USD
+0.00
(+0.00%
)AT CLOSE (AS OF Aug 15, 2025)
$244M
MARKET CAP
-
P/E Ratio
-1.1
EPS
$3.8
52 Week High
$0.86
52 Week Low
LIFE SCIENCES
Sector
ALLO Chart
Recent Chart
Price Action
1D
Candles
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
ALLO Technicals
ALLO Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $22K |
| Total Revenue | $22K |
| Cost Of Revenue | $14M |
| Costof Goods And Services Sold | $14M |
| Operating Income | -$273M |
| Selling General And Administrative | $65M |
| Research And Development | $192M |
| Operating Expenses | $273M |
| Investment Income Net | - |
| Net Interest Income | $20M |
| Interest Income | $20M |
| Interest Expense | $181K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | -$257M |
| Income Tax Expense | $443K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$258M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$257M |
| Ebitda | -$243M |
| Net Income | -$258M |
Revenue & Profitability
Earnings Performance
ALLO Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Total Assets | $549M |
| Total Current Assets | $303M |
| Cash And Cash Equivalents At Carrying Value | $75M |
| Cash And Short Term Investments | $75M |
| Inventory | - |
| Current Net Receivables | $1.9M |
| Total Non Current Assets | $245M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $81M |
| Short Term Investments | $217M |
| Other Current Assets | $9M |
| Other Non Current Assets | - |
| Total Liabilities | $127M |
| Total Current Liabilities | $36M |
| Current Accounts Payable | $5.4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $15M |
| Total Non Current Liabilities | $91M |
| Capital Lease Obligations | $91M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $91M |
| Other Current Liabilities | $15M |
| Other Non Current Liabilities | $7.8M |
| Total Shareholder Equity | $422M |
| Treasury Stock | - |
| Retained Earnings | -$1.8B |
| Common Stock | $212K |
| Common Stock Shares Outstanding | $195M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$200M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $14M |
| Capital Expenditures | $694K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $76M |
| Cashflow From Financing | $117M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $1.5M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$258M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $22K |
| Total Revenue | $22K |
| Cost Of Revenue | $14M |
| Costof Goods And Services Sold | $14M |
| Operating Income | -$273M |
| Selling General And Administrative | $65M |
| Research And Development | $192M |
| Operating Expenses | $273M |
| Investment Income Net | - |
| Net Interest Income | $20M |
| Interest Income | $20M |
| Interest Expense | $181K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | -$257M |
| Income Tax Expense | $443K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$258M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$257M |
| Ebitda | -$243M |
| Net Income | -$258M |
ALLO News
ALLO Profile
Allogene Therapeutics Inc Profile
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Discover more tools and features to empower your trading
Explore FeaturesMarket data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.